Creative Biolabs has proudly developed the unique Native™ Antibody Discovery Platform to develop native monoclonal antibodies using antigen-specific B lymphocytes cytometry technology.
Current in vitro antibody display methods cannot provide antibodies with naturally paired heavy chain and light chain. For technical reasons, the natural pairings of heavy and light chains found in antibody-producing B cells are not retained as the combinatorial libraries are constructed, leading to a random pairing of VH and VL in those de novo or naïve human antibody libraries. This could potentially lead to the generation of antibody molecules that have suboptimal solubility or other biophysical characteristics. Thereby, antibodies derived from these technologies most likely do not represent the naturally cognate heavy and light chains.
Another limitation often observed is that antibody derived from in vitro antibody display methods generally have moderate affinity to the targets, often in the 1-50 nM KD range, so they often require further affinity maturation before used as potential therapeutics. This is due to a practical limitation to the library size and hence diversity that can be constructed. Phage libraries are restricted to about 1010 to 1011 total diversity by the efficiency of bacterial transformation as well as by the practical limit of phage particle density of about 1013/mL.
To solve this problem, Creative Biolabs has developed the exclusive Native™ Antibody Discovery Platform to isolate single antigen-specific plasma cells to retrieve native antibodies with extremely high in vivo specificity and affinity. Moreover, this new technology allows us to select a large number of antibody candidates at once. In addition, the selection only takes 2-3 weeks post-immunization. It should be considered by far the most efficient way in developing native monoclonal antibodies from humans, rabbits, rats, mice, chicken and other species such as camelids, sheep, monkeys, dogs and even cows. For initiating native antibody development, single B cells need to be isolated and identified. Based on the principles used, the existing techniques can be classified into two groups, the one based on cell physical properties and the other one based on cellular biological characteristics.
Fig 1. Some single cell isolation technologies (Ping Hu, et al. 2016)
As a pioneer and the undisputed global leader in antibody discovery and manufacturing, Creative Biolabs offers native monoclonal antibodies for both academic and clinical use. Our highly professional scientists are confident in providing the domestic and international customers with the best possible services while at the most competitive price.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.